THE CIGNA GROUP(CI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CI THE CIGNA GROUP

Trading 11-22 09:34:44 EST

329.25

-0.82

-0.25%

High330.02	Low328.44	Vol15.25K
Open329.66	D1 Closing330.07	Amplitude0.48%
Mkt Cap91.58B	Tradable Cap91.15B	Total Shares278.15M
T/O5.02M	T/O Rate0.01%	Tradable Shares276.86M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CI","market":"US","secType":"STK","nameCN":"THE CIGNA GROUP","latestPrice":329.245,"timestamp":1732286082676,"preClose":330.07,"halted":0,"volume":15247,"delay":0,"floatShares":276858806,"shares":278152606,"eps":10.569287,"marketStatus":"Trading","change":-0.825,"latestTime":"11-22 09:34:44 EST","open":329.655,"high":330.015,"low":328.44,"amount":5021236.1139899995,"amplitude":0.004772,"askPrice":330.13,"askSize":100,"bidPrice":328.43,"bidSize":100,"shortable":3,"etf":0,"ttmEps":10.569287,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732309200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":330.07,"dividendRate":0.016492,"preHourTrading":{"tag":"盘前","latestPrice":330,"preClose":330.07,"latestTime":"08:38 EST","volume":38,"amount":12471.9401,"timestamp":1732282706074},"postHourTrading":{"tag":"盘后","latestPrice":330.07,"preClose":330.07,"latestTime":"19:32 EST","volume":225913,"amount":74552856.5366,"timestamp":1732235535667},"volumeRatio":0.824122,"impliedVol":0.2485,"impliedVolPercentile":0.4921},"requestUrl":"/m/hq/s/CI/tweets","defaultTab":"tweets","newsList":[{"id":"2485445105","title":"Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2485445105","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485445105?lang=en_us&edition=fundamental","pubTime":"2024-11-22 01:13","pubTimestamp":1732209180,"startTime":"0","endTime":"0","summary":"The focus shifts back to regualr pipleine updates in the biotech sector with the end of the third-quarter earnings season. Among these, Sage Therapeutics, Inc. SAGE and Incyte INCY were in focus this week as investors were disappointed with study failures.Sage Therapeutics announced disppointing top-line results from the mid-stage study on dalzanemdor . The phase II DIMENSION Study was a 12-week, double-blind, placebo-controlled study to evaluate the effects of dalzanemdor in participants with cognitive impairment  associated with Huntington’s Disease . A total of 189 participants were randomized.However, the study did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the Symbol Digit Modalities Test , a measure of cognitive function, at day 84, the primary endpoint.SAGE will also discontinue the ongoing PURVIEW Study, an open-label safety study of dalzanemdor in participants with HD.PYX-201 achieved a confir","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-sage-incy-171300122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0203347892.USD","SG9999001176.USD","IE00B19Z3581.USD","LU0203345920.USD","BTC","BK4585","IE00BLSP4452.SGD","LU2023250504.SGD","LU2461242641.AUD","SG9999014542.SGD","LU0109394709.USD","LU1989771016.USD","LU0985320562.USD","LU0868494617.USD","SG9999014559.SGD","LU0965509283.SGD","MRK","LU1059921491.USD","IE00BJT1NW94.SGD","LU2361045086.USD","LU1093756325.SGD","IE0002270589.USD","IE00BSNM7G36.USD","LU1093756168.USD","LU0211331839.USD","LU1917777945.USD","IE0002141913.USD","PYXS","SAGE","INCY","LU1116320737.USD","SG9999002224.SGD","SG9999002232.USD","LU1061106388.HKD","LU0289739699.SGD","BK4533","JAZZ","CI","IE0009355771.USD","LU1066051498.USD","BK4588","LU2112291526.USD","LU1989772840.SGD","LU1066051811.HKD","LU0070302665.USD","LU1989772923.USD","LU1291159041.SGD","LU0238689110.USD","BK4559","LU1941712348.USD"],"gpt_icon":0},{"id":"2485410617","title":"SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2485410617","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485410617?lang=en_us&edition=fundamental","pubTime":"2024-11-21 23:56","pubTimestamp":1732204560,"startTime":"0","endTime":"0","summary":"Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor , for treating cognitive impairment  associated with Huntington’s Disease  failed to meet the primary endpoint.The double-blind, placebo-controlled DIMENSION study evaluated the effects of dalzanemdor in participants with CI associated with HD.Top-line data from the study showed that dalzanemdor failed to demonstrate a statistically significant difference from baseline compared to placebo on the Symbol Digit Modalities Test, a measure of cognitive function, at day 84. This was the primary endpoint of the study.The stock hit its 52-week low on the pipeline setback. Year to date, shares of Sage Therapeutics have plunged 77.3% compared with the industry’s decline of 8.5%.An inherited disorder, HD, causes nerve cells  in brain parts to gradually break down and die. CI is one of the most under-recognized aspects of HD. Currently, no treatment options are available to improve HD-related cognitive ef","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sages-dalzanemdor-fails-meet-goal-155600924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","LU1035775433.USD","LU0354030511.USD","IE0002270589.USD","PD","IE00BWXC8680.SGD","SAGE","SPRO","LU0058720904.USD","LU0079474960.USD","LU1778281490.HKD","LU0942090050.USD","BK4550","BK4196","LU0820562030.AUD","IE00B1XK9C88.USD","BK4567","SG9999001440.SGD","BK4581","LU0820561909.HKD","CI","IMCR","LU1169589451.USD","LU2756315664.SGD","BK4504","CSTL","LU0689472784.USD","LU0234572021.USD","HD","LU0943347566.SGD","LU1551013342.USD","LU1093756325.SGD","LU0823411888.USD","LU0823434583.USD","BK4139","BK4585","BK4083","BK4533","BK4588","BK4023","IE00BSNM7G36.USD","LU0823434740.USD","MCI","BK4505","LU1674673428.USD","IE00B19Z3B42.SGD","LU1162221912.USD","LU1551013425.SGD","LU2756315318.SGD","LU1169590202.USD"],"gpt_icon":0},{"id":"2485510948","title":"Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2485510948","media":"PR Newswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485510948?lang=en_us&edition=fundamental","pubTime":"2024-11-21 08:19","pubTimestamp":1732148340,"startTime":"0","endTime":"0","summary":"Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review  from the HERIZON-BTC-01 clinical trial. The FDA approval of Ziihera is based on compelling data from the HERIZON-BTC-01 trial, which included the evaluation of zanidatamab as a single agent in previously treated HER2-positive  BTC and is the largest Phase 2b clinical trial to date specifically for this patient population. The trial achieved its primary endpoint of confirmed objective response rate  by independent central review  and results were presented at the American Society of Clinical Oncology  Annual Meeting 2023,published in The Lancet Oncology,and included in the 2023 Best of","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JlAZfc0NY41AU1qFnWFkeg--~B/aD0yODg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/978aa3435328e1c4e67d713d9059317d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JlAZfc0NY41AU1qFnWFkeg--~B/aD0yODg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/978aa3435328e1c4e67d713d9059317d"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-announces-u-fda-001900650.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-announces-u-fda-001900650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1261432733.SGD","IE00BSNM7G36.USD","BK4532","CDC","LU0289739699.SGD","BTC","IE00B19Z3B42.SGD","BK4588","BK4533","LU1059921491.USD","IE00B19Z3581.USD","LU0058720904.USD","IE0002270589.USD","BK4196","LU0868494617.USD","CI","JAZZ","BK4162","BK4585","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","IHC","BK4007"],"gpt_icon":0},{"id":"2485767931","title":"Cigna Group Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2485767931","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485767931?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:44","pubTimestamp":1732139040,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Cigna Group  inched 0.28% higher to $323.39 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index  remaining mostly unchanged at 5,917.11 and the Dow Jones Industrial Average  rising 0.32% to 43,408.47.This was the stock's third consecutive day of gains.Cigna Group closed $47.44 below its 52-week high , which the company achieved on September 16th.The stock underperformed when compared to some of its competitors Wednesday, as UnitedHealth Group Inc.  rose 4.07% to $600.50, CVS Health Corp.  rose 1.90% to $56.83, and Elevance Health Inc.  rose 0.83% to $397.48.Trading volume  remained 52,250 below its 50-day average volume of 1.6 M.Data source: Dow Jones Market Data, FactSet. Data compiled November 20, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently f","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CI"],"gpt_icon":0},{"id":"2485369121","title":"Dr. Oz Goes from TV to the Most Important Job in Healthcare. Here's What CMS Actually Does. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2485369121","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485369121?lang=en_us&edition=fundamental","pubTime":"2024-11-21 03:09","pubTimestamp":1732129740,"startTime":"0","endTime":"0","summary":"President-elect Donald Trump's announcement late Tuesday that he would appoint Dr. Mehmet Oz as administrator of the Centers for Medicare and Medicaid Services puts a man best known for hosting a television talk show into what might be the most important job in the U.S. healthcare system.The CMS administrator is not the most high-profile health official in any presidential administration. The current administrator, Chiquita Brooks-LaSure, is far from a household name. The post is, however, enormously consequential. It touches nearly every healthcare provider, healthcare institution, and healthcare company in the country. It has a direct hand in the care of nearly half of all Americans through the insurance programs it funds or operates.Oz, a surgeon with an MD and an M.B.A. from the University of Pennsylvania, is best known for hosting \"The Dr. Oz Show,\" a daytime television program where for years presented health cures that were often not backed by evidence.\"There's an unending amoun","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4100","LU0795875086.SGD","LU2271345857.HKD","LU1854104046.USD","UNH","LU0683600562.USD","LU1032466523.USD","LU0203347892.USD","LU0354030511.USD","LU1066051498.USD","IE00B2B36J28.USD","LU0348723411.USD","SG9999001176.USD","LU0868494617.USD","SG9999018857.SGD","LU1983299246.USD","LU0211331839.USD","SGXZ57979304.SGD","IE00BFSS7M15.SGD","IE00B19Z3B42.SGD","IE00B894F039.SGD","LU0211326755.USD","IE0034235303.USD","LU0320765646.SGD","LU2089284900.SGD","LU1551013342.USD","HCSG","LU0203345920.USD","LU0456855351.SGD","LU1720051108.HKD","LU1196500208.SGD","LU1496350502.SGD","CI","LU1244550577.SGD","LU1023059063.AUD","IE00B19Z8W00.USD","LU0077335932.USD","TV","LU2360032135.SGD","IE00B7SZLL34.SGD","LU0345770308.USD","LU2491050154.USD","JNJ","BK4137","HUM","LU1037948897.HKD","IE00B4R5TH58.HKD","CMS","LU0390134368.USD"],"gpt_icon":0},{"id":"2484146147","title":"After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2484146147","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484146147?lang=en_us&edition=fundamental","pubTime":"2024-11-20 23:36","pubTimestamp":1732116973,"startTime":"0","endTime":"0","summary":"On Wednesday, Sage Therapeutics Inc revealed topline results from the Phase 2 DIMENSION Study of dalzanemdor  in participants with cognitive impairment  associated with Huntington’s Disease , an inherited brain disorder that causes nerve cells in the brain to break down and die.In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test  at Day 84.Also Read: After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce. SDMT is used for cognitive evaluation, and measures sustained attention, processing speed, visual scanning, and motor speed.Based on these results, the company does not plan to develop dalzanemdor further.In October, Sage Therapeutics released topline results from the Phase 2 LIGHTWAVE study to evaluate the effects of dalzanemdor  in participants with mild cognitive impairment  or mild dementia due toAlzheimer's Disease .This a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XyFKzp6muhv8s2xUnRZDfw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/8af048e53d820bdd0358bcf43d65195c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XyFKzp6muhv8s2xUnRZDfw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/8af048e53d820bdd0358bcf43d65195c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/failed-alzheimers-study-sage-therapeutics-153613183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","LU0942090050.USD","LU0689472784.USD","LU0943347566.SGD","LU1674673691.USD","LU2756315664.SGD","SAGE","LU1778281490.HKD","LU0868494708.USD","MCI","BK4550","BK4504","SG9999001440.SGD","LU1989772923.USD","BK4083","BK4196","LU1496350171.SGD","BK4139","LU1929549753.HKD","IE00BZ1G4Q59.USD","BK4581","IE00BSNM7G36.USD","LU0320765646.SGD","LU1069344957.HKD","LU0079474960.USD","LU1093756325.SGD","LU1261432733.SGD","IE00B1XK9C88.USD","LU0820561909.HKD","LU1059921491.USD","IE00BKVL7J92.USD","HD","LU1989772840.SGD","LU1674673428.USD","LU0820562030.AUD","IE00B19Z3B42.SGD","BK4567","LU1093756168.USD","BK4534","CI","LU0354030438.USD","LU0823434583.USD","LU0289739699.SGD","IE0002270589.USD","LU1496350502.SGD","IE00BWXC8680.SGD","LU0234572021.USD","IE00B19Z3581.USD","BK4585","LU1551013425.SGD"],"gpt_icon":0},{"id":"2484110085","title":"CVS, OptumRx, Express sue FTC over insulin cost case, Bloomberg Law says","url":"https://stock-news.laohu8.com/highlight/detail?id=2484110085","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484110085?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:41","pubTimestamp":1732113700,"startTime":"0","endTime":"0","summary":"The three largest pharmacy benefit managers in the U.S., CVS Caremark (CVS), UnitedHealth’s (UNH) OptumRx, and Cigna’s (CI) Express Scripts, have f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cvs-optumrx-express-sue-ftc-over-insulin-cost-case-bloomberg-law-says?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cvs-optumrx-express-sue-ftc-over-insulin-cost-case-bloomberg-law-says?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0097036916.USD","LU0342679015.USD","LU1791710400.SGD","IE00B4JS1V06.HKD","SG9999013999.USD","UNH","LU0058720904.USD","LU0557290698.USD","LU0496365809.HKD","LU0708995401.HKD","LU0149725797.USD","LU0203347892.USD","LU0683600562.USD","LU0011850046.USD","IE00BJJMRX11.SGD","LU1066051498.USD","IE00BKVL7J92.USD","LU0820561909.HKD","LU1074936037.SGD","LU0738911758.USD","LU1814569148.SGD","LU2360032135.SGD","LU1674673691.USD","LU1267930573.SGD","CVS","LU2087625088.SGD","LU0320765059.SGD","FTC","LU2125154935.USD","LU2324357040.USD","LU2089284900.SGD","LU1548497426.USD","LU0211326755.USD","LU0289739699.SGD","LU2211815571.USD","LU0310800379.SGD","LU2236285917.USD","LU0795875169.SGD","CI","LU2023251221.USD","SG9999002224.SGD","LU1267930730.SGD","SG9999014906.USD","IE00BFSS8Q28.SGD","LU0949170772.SGD","LU2357305700.SGD","LU0345770308.USD","LU0256863811.USD","LU1778281490.HKD"],"gpt_icon":0},{"id":"2484944331","title":"Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2484944331","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484944331?lang=en_us&edition=fundamental","pubTime":"2024-11-20 19:30","pubTimestamp":1732102200,"startTime":"0","endTime":"0","summary":"The Phase 2 DIMENSION Study did not meet its primary endpoint. Dalzanemdor was generally well-tolerated; no new safety signals were observed. Based on these data, the Company does not plan further development of dalzanemdor. CAMBRIDGE, Mass., November 20, 2024----Sage Therapeutics, Inc.  today announced topline results from the Phase 2 DIMENSION Study of dalzanemdor  in participants with cognitive impairment  associated with Huntington’s Disease . In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test  at Day 84. Analyses of secondary endpoints did not demonstrate statistically significant or clinically meaningful differences in participants treated with dalzanemdor compared to placebo. Based on these results, the Company does not plan further development of dalzanemdor.\"We are disappointed by the results of the DIMENSION Study, especially for the individua","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jlqGxr4P6ViRdaWAih_NWg--~B/aD0xMzg3O3c9NDQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/8cccd96bb5295af2aa0755b54379f770","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jlqGxr4P6ViRdaWAih_NWg--~B/aD0xMzg3O3c9NDQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/8cccd96bb5295af2aa0755b54379f770"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-therapeutics-announces-topline-results-113000535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1929549753.HKD","LU0943347566.SGD","BK4567","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","SAGE","SG9999001440.SGD","LU1093756168.USD","LU0354030438.USD","LU1551013425.SGD","BK4139","LU0868494617.USD","BK4566","LU0820562030.AUD","LU1261432733.SGD","LU0320765646.SGD","LU0820561818.USD","LU0079474960.USD","IE00BWXC8680.SGD","LU0823434583.USD","LU0823434740.USD","LU1035775433.USD","IE00BKVL7J92.USD","LU2756315318.SGD","HD","LU0689472784.USD","BK4533","LU0820561909.HKD","LU0058720904.USD","BK4534","LU0868494708.USD","LU1778281490.HKD","IE00BZ1G4Q59.USD","BK4504","LU0823411888.USD","LU0942090050.USD","CI","LU1674673428.USD","LU1496350502.SGD","LU2756315664.SGD","IE00B1XK9C88.USD","LU1989772840.SGD","BK4196","LU1162221912.USD","IE00B19Z3581.USD","BK4083","BK4550","LU1496350171.SGD","BK4585","LU0354030511.USD"],"gpt_icon":0},{"id":"2484904515","title":"Cigna, CVS, UnitedHealth PBMs sue FTC over insulin prices case","url":"https://stock-news.laohu8.com/highlight/detail?id=2484904515","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484904515?lang=en_us&edition=fundamental","pubTime":"2024-11-20 06:09","pubTimestamp":1732054143,"startTime":"0","endTime":"0","summary":"FinkAvenue/iStock Editorial via Getty ImagesPharmacy benefit managers owned by Cigna , CVS Heath , and UnitedHealth Group  have sued the Federal Trade Commission, arguing that a case the agency has filed against them regarding inflated insulin prices is unconstitutional. The lawsuit was filed","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1384455170/image_1384455170.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1384455170/image_1384455170.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4309353-cigna-cvs-unitedhealth-pbms-sue-ftc-insulin-prices-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["CVS","LU0545039389.USD","IE00B19Z3B42.SGD","LU0122379950.USD","LU1059921491.USD","LU2125154778.USD","LU0496365809.HKD","IE00BZ1G4Q59.USD","LU0149725797.USD","LU0234572021.USD","BK4566","IE00BJJMRX11.SGD","IE00B19Z8X17.USD","LU0320765059.SGD","IE00B1BXHZ80.USD","LU1003077747.HKD","LU1064131342.USD","LU2362541513.USD","LU2087625088.SGD","LU1261432733.SGD","LU0256863811.USD","LU0456855351.SGD","LU0079474960.USD","SG9999001176.SGD","LU0029864427.USD","SG9999002224.SGD","LU0708994859.HKD","IE00BZ9MQY76.HKD","LU0058720904.USD","LU0689472784.USD","LU0708995401.HKD","LU1084165304.USD","LU2279689827.SGD","UNH","CI","LU0342679015.USD","LU0795875086.SGD","LU1153585028.USD","LU1720051108.HKD","LU1732799900.SGD","LU1267930573.SGD","LU1989771016.USD","LU1934455863.HKD","LU0943347566.SGD","BK4534","BK4504","BK4532","BK4581","IE00BJJMRZ35.SGD","IE00B775H168.HKD"],"gpt_icon":0},{"id":"2484156907","title":"Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2484156907","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484156907?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:18","pubTimestamp":1732051080,"startTime":"0","endTime":"0","summary":"However, declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds.PepsiCo’s shares have underperformed the Zacks Beverages – Soft drinks industry over the past year . The Zacks analyst believes that largely due to challenges in its North American operations since the start of 2024 that includes reduced consumer demand and product recalls in the QFNA segment, the company has underperformed over the past year. Additionally, adverse currency rates continue to pose challenges.Yet, it is well-poised to benefit from strength and resilience in core categories, diversified portfolio, modernized supply chain, improved digital capabilities and flexible go-to-market distribution systems. The company's international business continues to hallmark its overall performance.Other noteworthy reports we are featuring today include Alibaba Group Holding Ltd. , The Walt Disney Co.  and Trane Technologies ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-research-reports-eli-lilly-211800630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HBBD.SI","TT","LLY","MS","BABA","CI","DIS","PEP"],"gpt_icon":1},{"id":"2484920122","title":"UnitedHealth, CVS, Cigna Units Sue to Block FTC Case Against Drug Middlemen","url":"https://stock-news.laohu8.com/highlight/detail?id=2484920122","media":"MT Newswires Live","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484920122?lang=en_us&edition=fundamental","pubTime":"2024-11-20 01:06","pubTimestamp":1732035966,"startTime":"0","endTime":"0","summary":"Price: 581.21, Change: -8.44, Percent Change: -1.43","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z3581.USD","IE00B7KXQ091.USD","LU0965509283.SGD","LU2362541273.HKD","LU0053666078.USD","SG9999014880.SGD","UNH","LU0072461881.USD","LU1934455194.USD","LU2112291526.USD","LU1861558580.USD","LU0320765489.SGD","SG9999001176.USD","FTC","LU1291159041.SGD","LU2125154778.USD","IE00B19Z8X17.USD","LU0553294199.USD","LU0861579265.USD","LU1732800096.USD","IE00BKPKM429.USD","LU0238689110.USD","LU0203347892.USD","CVS","LU1983299246.USD","LU0211328371.USD","IE00B19Z9Z06.USD","LU0234572021.USD","LU2360032135.SGD","LU0211326755.USD","BK4196","LU0079474960.USD","BK4533","SG9999002232.USD","LU0128525929.USD","LU0289739699.SGD","LU0353189763.USD","BK4566","LU1670628061.USD","LU0211331839.USD","SG9999001176.SGD","BK4154","LU0162691827.USD","SGXZ99366536.SGD","LU0266013472.USD","IE00B19Z9505.USD","LU0823416689.USD","LU1066051811.HKD","CI"],"gpt_icon":0},{"id":"2484591472","title":"Cigna price target raised to $370 from $355 at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2484591472","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484591472?lang=en_us&edition=fundamental","pubTime":"2024-11-19 19:15","pubTimestamp":1732014937,"startTime":"0","endTime":"0","summary":"Wells Fargo raised the firm’s price target on Cigna  to $370 from $355 and keeps an Equal Weight rating on the shares as the firm updates Managed Care estimates post-election. All estimates assume the expiration of enhanced exchange subsidies for 2026, Wells notes. The firm believes Medicare Advantage risk/reward improves with Republicans, although areas of concern still exist.Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Omega exits stakes in Devon, Las Vegas Sands, KBR, and Paramount Global. Cigna  Surges after Saying It Will Not Buy Humana. Early notable gainers among liquid option names on November 11th. Morning Movers: Cigna climbs after confirming not pursuing Humana deal","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HcTdIUOW2CtceITEmT5QRg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/e08ef17a226cc4aa932fc167005beb50","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HcTdIUOW2CtceITEmT5QRg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/e08ef17a226cc4aa932fc167005beb50"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cigna-price-target-raised-370-111537100.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cigna-price-target-raised-370-111537100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CI"],"gpt_icon":0},{"id":"2484841169","title":"Cigna Group Stock Rises Monday, Still Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2484841169","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484841169?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:44","pubTimestamp":1731966240,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Cigna Group  inched 0.29% higher to $322.45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index  rising 0.39% to 5,893.62 and the Dow Jones Industrial Average  falling 0.13% to 43,389.60.The stock's rise snapped a four-day losing streak.Cigna Group closed $48.38 below its 52-week high , which the company reached on September 16th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as UnitedHealth Group Inc.  fell 0.44% to $589.65, CVS Health Corp.  rose 5.38% to $56.05, and Elevance Health Inc.  rose 0.00% to $400.70.Trading volume  remained 365,828 below its 50-day average volume of 1.6 M.Data source: Dow Jones Market Data, FactSet. Data compiled November 18, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CI"],"gpt_icon":0},{"id":"2484967493","title":"Wells Fargo Adjusts Price Target on Cigna to $370 From $355, Maintains Equalweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2484967493","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484967493?lang=en_us&edition=fundamental","pubTime":"2024-11-18 23:24","pubTimestamp":1731943498,"startTime":"0","endTime":"0","summary":"Cigna (CI) has an average outperform rating and a price target range of $355 to $438, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic research from major","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CI"],"gpt_icon":0},{"id":"2484282136","title":"Wells Fargo Sticks to Their Hold Rating for Cigna (CI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484282136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484282136?lang=en_us&edition=fundamental","pubTime":"2024-11-18 19:17","pubTimestamp":1731928642,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Steve Baxter maintained a Hold rating on Cigna (CI – Research Report) today and set a price target of $370.00. The company’s sh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-their-hold-rating-for-cigna-ci?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-their-hold-rating-for-cigna-ci?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CI"],"gpt_icon":0},{"id":"2484850639","title":"Analysts Offer Insights on Financial Companies: CI Financial (OtherCIXXF) and Capital One Financial (COF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484850639","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484850639?lang=en_us&edition=fundamental","pubTime":"2024-11-17 22:50","pubTimestamp":1731855015,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on CI Financial (CIXXF – Research Report) and Capital On...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-financial-companies-ci-financial-othercixxf-and-capital-one-financial-cof?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-financial-companies-ci-financial-othercixxf-and-capital-one-financial-cof?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU1201861249.SGD","BK4588","IE0002270589.USD","LU1861220207.SGD","LU0130103400.USD","IE00B19Z3B42.SGD","LU0868494617.USD","LU0211331839.USD","LU0289739699.SGD","LU1059921491.USD","LU1261432733.SGD","BK4166","IE00B19Z3581.USD","LU0980610538.SGD","LU2360107671.USD","LU0053666078.USD","LU0130102774.USD","LU0130518102.USD","COF","LU1861217088.USD","BK4516","IE00BSNM7G36.USD","LU0477156797.USD","LU0058720904.USD","LU0648000940.SGD","CI","LU1201861165.SGD","LU0648001328.SGD","BK4196"],"gpt_icon":0},{"id":"2483246538","title":"CI Financial May Resurrect U.S. IPO Plans, CEO Says -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2483246538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483246538?lang=en_us&edition=fundamental","pubTime":"2024-11-16 05:11","pubTimestamp":1731705060,"startTime":"0","endTime":"0","summary":"When it comes to planning for a U.S. IPO, maybe second time is the charm for CI Financial?On Thursday, CI Financial CEO Kurt MacAlpine said the Canadian company may resurrect its plans to take its U.S. wealth management business public in 2026. It first announced plans for a U.S. IPO in April 2022.\"We've been laser-focused, heads down on driving maximum integration, maximum growth, really setting up the business to continue to scale, which we've done,\" he said. \"But we'll continue to keep an eye on markets, see how the IPO market unfolds, and then look at the timing as it relates to all those factors.\". Last year, Toronto-based CI Financial paused plans to pursue an IPO for its U.S. wealth unit and instead sold a 20% stake in the unit to a consortium of investors that includes the Abu Dhabi Investment Authority and private-equity firm Bain Capital. CI Financial rebranded the U.S. wealth unit Corient in August 2023.This content was created by Barron's, which is operated by Dow Jones & C","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1059921491.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","IE00BSNM7G36.USD","IE0002270589.USD","BK4588","CI","LU0868494617.USD","LU1261432733.SGD","LU0058720904.USD","IE00B19Z3581.USD","BK4585","BK4196"],"gpt_icon":0},{"id":"2483307997","title":"CI Financial price target raised to C$28 from C$26 at TD Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2483307997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483307997?lang=en_us&edition=fundamental","pubTime":"2024-11-16 01:10","pubTimestamp":1731690620,"startTime":"0","endTime":"0","summary":"TD Securities raised the firm’s price target on CI Financial (CIXXF) to C$28 from C$26 and keeps a Buy rating on the shares. Published first on The...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ci-financial-price-target-raised-to-c28-from-c26-at-td-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ci-financial-price-target-raised-to-c28-from-c26-at-td-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CI","TD"],"gpt_icon":0},{"id":"2483253787","title":"Want dividend safety, consistency, growth, and a yield? See these 10 names","url":"https://stock-news.laohu8.com/highlight/detail?id=2483253787","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483253787?lang=en_us&edition=fundamental","pubTime":"2024-11-15 23:39","pubTimestamp":1731685160,"startTime":"0","endTime":"0","summary":"PM Images  When it comes to dividend investing, most investors want safety, consistency, growth, and yield, but finding that exact combination can be a challenge. \nAs a result, Seeking Alpha screened a list of stocks that fit the mold for the above requirements, and","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4295087-want-dividend-safety-consistency-growth-and-a-yield-see-these-10-names","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["LU0054578231.USD","BK4107","LU0234572021.USD","US30Y.BOND","BK4171","LU0238689110.USD","LU0265550946.USD","BK4117","IE00BBT3K403.USD","SG9999015986.USD","LU0320765646.SGD","QCOM","CI","LU1093756325.SGD","BK4161","LU2361044865.SGD","MATX","LU1989771016.USD","IE00BJT1NW94.SGD","SG9999014575.USD","LU1037948897.HKD","LU1066051498.USD","LU0861579265.USD","DDS","RHI","LU1037948541.HKD","BK4564","US3Y.BOND","BK4573","US10Y.BOND","US5Y.BOND","US7Y.BOND","BK4141","LMT","LU2023250843.SGD","US2Y.BOND","SG9999001440.SGD","BK4220","LU1974910355.USD","US12M.BOND","IE00B4R5TH58.HKD","LU1989772923.USD","US6M.BOND","MRK","LU1119994496.HKD","AFG","SG9999015358.SGD","LU1066051225.USD","IIPR","SNA"],"gpt_icon":0},{"id":"2483136032","title":"Larry Robbins' Strategic Moves in Q3 2024: A Deep Dive into Tenet Healthcare's Significant Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2483136032","media":"GuruFocus.com","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483136032?lang=en_us&edition=fundamental","pubTime":"2024-11-15 10:13","pubTimestamp":1731636829,"startTime":"0","endTime":"0","summary":"Insights from Glenview Capital Management's Latest 13F Filing. Larry Robbins , the founder of Glenview Capital Management, has made notable adjustments to his investment portfolio in the third quarter of 2024. Established in 2000, Glenview Capital is renowned for its rigorous fundamental research and strategic investment in primarily U.S. markets, with some exposure in Western Europe. The firm operates through two main funds: the Glenview Funds and the Glenview Opportunity Funds, focusing on long/short and concentrated opportunistic investments respectively.GuruFocus has detected 3 Warning Signs with CVS.Seagate Technology Holdings PLC , purchasing 402,771 shares, which now comprise 0.85% of the portfolio, valued at $44.12 million.Western Digital Corp , with 434,276 shares, making up about 0.57% of the portfolio, valued at $29.66 million.Global Payments Inc  saw an addition of 1,022,840 shares, resulting in a total of 4,141,160 shares. This represents a 32.8% increase in share count, v","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ea7v.aNjN.mXBa7mJWY9WQ--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/3dafc4c0d558f90267f23f76eb5ce825","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ea7v.aNjN.mXBa7mJWY9WQ--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/3dafc4c0d558f90267f23f76eb5ce825"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/larry-robbins-strategic-moves-q3-021349257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GPN","LU0878866978.SGD","WDC","CI","LU0187121727.USD","IE00BKVL7J92.USD","SG9999014005.SGD","LU0130103400.USD","IE00B894F039.SGD","BK4503","LU2324357040.USD","THC","IE00B19Z9P08.USD","IE0002270589.USD","LU0068578508.USD","LU2236285917.USD","CNC","LU1201861249.SGD","LU0203347892.USD","LU0310800379.SGD","LU0052756011.USD","LU0648001328.SGD","LU1506573853.SGD","STX","LU0211328371.USD","LU0211331839.USD","BK4154","HCA","LU0128525929.USD","CVS","BK4552","IE00BZ1G4Q59.USD","BK4510","LU0058720904.USD","DD","GOTU","LU0070302665.USD","LU1267930490.SGD","BK4531","LU1150488135.SGD","LU0708994859.HKD","LU1861217088.USD","LU0203345920.USD","LU0963586101.USD","CTVA","LU1069347547.HKD","LU1489326972.SGD","BK4506","ALIT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.thecignagroup.com","stockEarnings":[{"period":"1week","weight":0.0191},{"period":"1month","weight":0.0397},{"period":"3month","weight":-0.0676},{"period":"6month","weight":-0.0076},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1023}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.642857,"avgChangeRate":0.018602},{"month":2,"riseRate":0.571429,"avgChangeRate":0.009544},{"month":3,"riseRate":0.595238,"avgChangeRate":0.016882},{"month":4,"riseRate":0.536585,"avgChangeRate":0.002534},{"month":5,"riseRate":0.595238,"avgChangeRate":0.019148},{"month":6,"riseRate":0.627907,"avgChangeRate":0.006999},{"month":7,"riseRate":0.348837,"avgChangeRate":-0.008751},{"month":8,"riseRate":0.627907,"avgChangeRate":0.025016},{"month":9,"riseRate":0.465116,"avgChangeRate":-0.011042},{"month":10,"riseRate":0.581395,"avgChangeRate":-0.001156},{"month":11,"riseRate":0.744186,"avgChangeRate":0.045438},{"month":12,"riseRate":0.547619,"avgChangeRate":0.022806}],"exchange":"NYSE","name":"THE CIGNA GROUP","nameEN":"THE CIGNA GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"THE CIGNA GROUP(CI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest THE CIGNA GROUP(CI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"THE CIGNA GROUP,CI,THE CIGNA GROUP股票,THE CIGNA GROUP股票老虎,THE CIGNA GROUP股票老虎国际,THE CIGNA GROUP行情,THE CIGNA GROUP股票行情,THE CIGNA GROUP股价,THE CIGNA GROUP股市,THE CIGNA GROUP股票价格,THE CIGNA GROUP股票交易,THE CIGNA GROUP股票购买,THE CIGNA GROUP股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"THE CIGNA GROUP(CI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest THE CIGNA GROUP(CI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction